Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

NCT03126617 | Unknown

• 1 other identifier: EAP-01-CA204
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.

Conditions

Multiple Myeloma

Interventions

Elotuzumab BIOLOGICAL

Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.

Also known as: Empliciti, BMS-901608

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The illness must be serious or life threatening
• There are no other viable options (including approved products or active clinical trials)
• There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time

Sponsors & Collaborators

• Bristol-Myers Squibb: lead

Related Links

• Information for Early Patient Access to Investigational Drugs

MeSH Terms

Conditions

Multiple Myeloma

Interventions

elotuzumab

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Bristol-Myers Squibb

  Bristol-Myers Squibb

  STUDY DIRECTOR

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 18, 2017
• First Posted: April 24, 2017
• Last Updated: November 29, 2021

Record last verified: 2021-11